WA
BSTC

Winfield Associates’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Winfield Associates’s Portfolio BSTC Stock Details BSTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-4,265
Closed -$241K – 137
2020
Q1 		$241K Sell
4,265
-715
-14% -$40.7K 0.15% 91
2019
Q4 		$284K Sell
4,980
-20
-0.4% -$1.06K 0.13% 106
2019
Q3 		$268K Buy
+5,000
New +$291K 0.13% 107

Other funds holding BSTC

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Winfield Associates's BSTC Position: Q2 2020 in Review

Winfield Associates sold out of BioSpecifics Technologies Corp. (BSTC) in Q2 2020, closing a stake of 4,265 shares — an estimated $241K sold.

Winfield Associates first reported a position in BSTC in Q3 2019 and held it in 3 quarters. The position peaked at $284K in Q4 2019. 116 funds tracked by Wall St. Rank hold BSTC as of Q2 2020.

  • Winfield Associates reported no remaining BioSpecifics Technologies Corp. position as of Q2 2020 after selling out during the quarter.
  • Winfield Associates sold 4,265 BioSpecifics Technologies Corp. shares in Q2 2020, an estimated $241K.
  • Winfield Associates first reported a position in BioSpecifics Technologies Corp. in Q3 2019 and held it in 3 quarters.
  • Winfield Associates's BioSpecifics Technologies Corp. position peaked at $284K in Q4 2019.
  • 116 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q2 2020.

Based on Winfield Associates's 13F filing for Q2 2020, filed 14 Aug 2020.